Journal article
C. Mariano, A. Alves, A. Medeiros, J. Chora, M. Antunes, M. Futema, S. Humphries, M. Bourbon
Clinical genetics, vol. 97(3), 2020 Mar, pp. 457-466
Clinical genetics, vol. 97(3), 2020 Mar, pp. 457-466
DOI:
10.1111/cge.13697
Semantic Scholar
DOI
PubMed
Cite
Cite
APA
Click to copy
Mariano, C., Alves, A., Medeiros, A., Chora, J., Antunes, M., Futema, M., … Bourbon, M. (2020). The familial hypercholesterolaemia phenotype: Monogenic familial hypercholesterolaemia, polygenic hypercholesterolaemia and other causes. Clinical Genetics, 97(3), 457–466. https://doi.org/10.1111/cge.13697
Chicago/Turabian
Click to copy
Mariano, C., A. Alves, A. Medeiros, J. Chora, M. Antunes, M. Futema, S. Humphries, and M. Bourbon. “The Familial Hypercholesterolaemia Phenotype: Monogenic Familial Hypercholesterolaemia, Polygenic Hypercholesterolaemia and Other Causes.” Clinical genetics 97, no. 3 (March 2020): 457–466.
MLA
Click to copy
Mariano, C., et al. “The Familial Hypercholesterolaemia Phenotype: Monogenic Familial Hypercholesterolaemia, Polygenic Hypercholesterolaemia and Other Causes.” Clinical Genetics, vol. 97, no. 3, Mar. 2020, pp. 457–66, doi:10.1111/cge.13697.
BibTeX Click to copy
@article{c2020a,
title = {The familial hypercholesterolaemia phenotype: Monogenic familial hypercholesterolaemia, polygenic hypercholesterolaemia and other causes},
year = {2020},
month = mar,
issue = {3},
journal = {Clinical genetics},
pages = {457-466},
volume = {97},
doi = {10.1111/cge.13697},
author = {Mariano, C. and Alves, A. and Medeiros, A. and Chora, J. and Antunes, M. and Futema, M. and Humphries, S. and Bourbon, M.},
month_numeric = {3}
}
Abstract
Familial hypercholesterolaemia (FH) is a monogenic disorder characterised by high low‐density lipoprotein cholesterol (LDL‐C) concentrations and increased cardiovascular risk. However, in clinically defined FH cohorts worldwide, an FH‐causing variant is only found in 40%‐50% of the cases. The aim of this work was to characterise the genetic cause of the FH phenotype in Portuguese clinical FH patients. Between 1999 and 2017, 731 index patients (311 children and 420 adults) who met the Simon Broome diagnostic criteria had been referred to our laboratory. LDLR, APOB, PCSK9, APOE, LIPA, LDLRAP1, ABCG5/8 genes were analysed by polymerase chain reaction amplification and Sanger sequencing. The 6‐SNP LDL‐C genetic risk score (GRS) for polygenic hypercholesterolaemia was validated in the Portuguese population and cases with a GRS over the 25th percentile were considered to have a high likelihood of polygenic hypercholesterolaemia. An FH‐causing mutation was found in 39% of patients (94% in LDLR, 5% APOB and 1% PCSK9), while at least 29% have polygenic hypercholesterolaemia and 1% have other lipid disorders. A genetic cause for the FH phenotype was found in 503 patients (69%). All known causes of the FH phenotype should be investigated in FH cohorts to ensure accurate diagnosis and appropriate management.
